

**To the Business Editors
For Immediate Release**

Trustar Capital Completes Investment in Global Medical Technology Leader MedAlliance

(Hong Kong, 17 March 2021) Trustar Capital (formerly known as CITIC Capital Partners), a private equity affiliate of CITIC Capital Holdings Limited, announced that it has completed its investment in Swiss-based global leading medical technology company MedAlliance SA ('The Company' or 'MedAlliance'), becoming MedAlliance's single largest shareholder. The investment will be used to fund the commercialization and roll-out of MedAlliance's key product SELUTION SLR™.

Headquartered in Nyon, Switzerland, MedAlliance is dedicated to developing and manufacturing of innovative drug-eluting balloons (DEBs) for patients suffering from life-threatening coronary and peripheral arterial disease. Using breakthrough proprietary technology, MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with SELUTION SLR™. The unique technology has demonstrated impressive clinical trial results and is the first DEB company in the world to receive US Food and Drug Administration (FDA) Breakthrough Device Designation Status for a coronary DEB. Recently MedAlliance has received the fourth breakthrough designation award by FDA for its sirolimus DEB. MedAlliance's technology is now available in Europe and other countries that recognize CE Mark and is in the process of completing FDA registration in the U.S.

Cardiovascular diseases (CVDs) are the number 1 cause of death globally. "Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019", a report from J Am Coll Cardiol showed that total number of CVDs cases reached 523 million in 2019. According to a study published by the National Center for Cardiovascular Diseases in September 2020, there has been continued growth in the number of patients with cardiovascular disease in China. The demand for quality treatment and the development of newer technology related to coronary and peripheral diseases will continue to rise, especially in markets like China. MedAlliance has already commenced clinic trials of its core product SELUTION SLR™ in the Chinese market, and will continue to actively expand its footprints there.

"We are very pleased to have Trustar as a valued partner and to have established a strong relationship with their team over a substantial period of time. Their in-depth knowledge and expertise in the global medical device market will be of tremendous benefit to us", said Jeffrey B. JUMP, Chairman and CEO of MedAlliance. "Validation from this highly successful and respected organization represents a significant endorsement of both our technology and our team and will help us to improve and extend the lives of patients around the world."

Boon CHEW, Senior Managing Director and Managing Partner of Trustar Capital, said: "The global market size for medical devices addressing coronary and peripheral diseases has increased in recent years. In particular, we have seen exciting breakthroughs in technological development and clinical adoption in the interventional device space. MedAlliance has a very solid team of seasoned veterans with strong R&D

capability and has successfully developed innovative products that lead the market in terms of technology and registration progress. We have been closely following MedAlliance for a considerable amount of time and have established a strong relationship with its management team. We are excited to be working together and will continue to bring good news to coronary and peripheral disease patients worldwide.”

Haiwen & Partners provided legal advice to Trustar Capital on the transaction.

- Ends -

About MedAlliance

Founded in 2008, MedAlliance is a privately-owned medical technology company. It is headquartered in Nyon (Switzerland), with facilities in Irvine (California), Glasgow (UK) and Singapore. MedAlliance specializes in the development of ground-breaking technology and commercialization of advanced drug device combination products for the treatment of coronary and peripheral artery diseases. For further information, please visit <https://medalliance.com>.

About Trustar Capital

Trustar Capital (formerly known as CITIC Capital Partners), focuses on control buyout opportunities globally and has completed over 79 investments since inception across China, Japan, U.S., Europe, etc. Trustar Capital currently manages USD7.6 billion of committed capital. For more information, please visit www.trustarcapital.com.

Trustar Capital is a private equity affiliate of CITIC Capital Holdings Limited. Founded in 2002, CITIC Capital Holdings Limited is an alternative investment management and advisory company. The firm manages over USD35 billion of capital across 90 funds and investment products through its multiple asset class platform covering private equity, real estate, structured investment & finance, and asset management. CITIC Capital has over 150 portfolio companies that span 11 sectors and employ over 800,000 people around the world.

For media enquiries, please contact:

Cindy TAM

Director, Corporate Relations

CITIC Capital Holdings Limited

Tel: +852 3710 6813

cindytam@citiccapiatal.com

Irene GAO

Senior Associate, Corporate Relations

CITIC Capital Holdings Limited

Tel: +852 3710 6814

irenegao@citiccapiatal.com